Flosonics is a medical device company that focuses on developing non-invasive sensors to improve the management of critically ill patients.
Flosonics's flagship smart-bandage product, the FloPatch, addresses unmet clinical needs of critically ill patients and the physicians, nurses, and paramedics who care for them in the ambulance, emergency department, operating room, and intensive care unit.
Forest Devices, Inc. is a medical device company based in Pittsburgh, Pennsylvania, with an additional office in Canada. Founded in 2014, the company focuses on developing innovative solutions for stroke detection. Its flagship product, AlphaStroke, is a non-invasive, AI-powered device designed for medical personnel to identify strokes in various environments, even before advanced imaging techniques like CT or MRI are available. This portable and durable device can detect both ischemic and hemorrhagic strokes, enabling practitioners to triage patients effectively and improve treatment outcomes. By streamlining the decision-making process in stroke management, AlphaStroke aims to reduce delays in critical care and enhance the overall frequency of stroke treatments.
OncoRes Medical Pty Ltd is an early-stage medical device company based in Nedlands, Australia, founded in 2014. The company specializes in developing a patented imaging technology that provides surgeons with real-time, micro-scale images of tissue stiffness and elasticity during breast cancer surgeries. This innovative tool integrates optical coherence tomography to enhance surgical accuracy, aiding in the differentiation between tumor and healthy tissue. OncoRes collaborates with leading researchers at the University of Western Australia and the Harry Perkins Institute of Medical Research, as well as breast cancer surgeons in the Western Australian public health system. With support from the Medical Research Commercialisation Fund, OncoRes Medical aims to improve clinical applications by enabling precise intraoperative assessments of tissue microstructure, ultimately striving to transform the standard of care in breast cancer treatment.
AMB Surgical is a developer of innovative medical devices aimed at treating pediatric deformities, particularly scoliosis. The company has created an electro-mechanical smart automated growing rod known as "FLYTE," which allows for precise and frequent non-surgical adjustments through sensor feedback. This technology enhances the capabilities of surgeons in managing complex cases involving pediatric scoliosis, dynamic external fixation for deformity correction, and applications related to long bone lengthening. By providing a solution that minimizes the need for invasive surgical procedures, AMB Surgical aims to improve treatment outcomes for children facing these conditions.
Auctus Surgical is focused on innovative solutions for treating pediatric scoliosis through its dynamic vertebral body tethering system. This system is designed for non-fusion scoliosis correction, allowing for non-surgical adjustments over time. By incorporating dynamic magnetic technology, Auctus enables surgeons to implement a spinal tethering system that facilitates growth modulation without the need for traditional surgical interventions. In addition to its primary product, Auctus has also licensed technology related to magnetically adjustable growing rods, which can be utilized for both pediatric scoliosis treatment and limb lengthening. This approach aims to improve outcomes for young patients by providing a less invasive alternative to conventional surgical methods.
Day Zero Diagnostics (DZD) is developing a new class of diagnostic that enables a physician to switch from broad spectrum antibiotic therapy to a targeted antibiotic in 5 hours rather than the 2-5 days that it typically takes today. Unlike other molecular diagnostics that can only detect a handful of specific targets, DZD uses the entire genomic sequence and our proprietary Keynome™ algorithm to identify a comprehensive range of bacterial pathogens and their resistance characteristics within hours.
Advanced Chemotherapy Technologies is a healthcare company that is developing breakthrough combination drug-device technologies for treating pancreatic cancer.
Eximis Surgical, founded in 2014 and headquartered in Louisville, Colorado, specializes in developing innovative technology for laparoscopic surgery. The company has created a specimen removal device that enables surgeons to efficiently extract large specimens through small incisions. This device utilizes radio frequency (RF) energized cutting wires, which are temporarily held in a containment bag, allowing for quick and safe specimen removal. By integrating seamlessly into existing physician protocols, Eximis Surgical's technology significantly reduces the time required for specimen extraction, minimizes patient discomfort, and ensures safe surgical outcomes. Additionally, the device separates specimens into narrow strips, facilitating the creation of clean tissue segments for accurate pathology identification, thereby enhancing the overall effectiveness of minimally invasive surgery.
The Otricath™ introduces a new perspective on therapy delivery. The platform technology delivers cancer-fighting agents to solid tumors with unparalleled control, predictability, and safety for optimal therapeutic benefit and minimal systemic toxicity.
NovaGray is focused on creating advanced companion diagnostic tests designed to enhance radiation therapy planning. The company develops biomarker-based tests that evaluate patients' sensitivity to radiation through a single blood sample. This approach allows healthcare practitioners to tailor treatment plans, including dosage and session sequencing, based on individual patient profiles. By personalizing standard treatments, NovaGray aims to improve patient outcomes while also reducing both complication and overall treatment costs.
2Morrow, Inc. is a digital health company based in Kirkland, Washington, that specializes in evidence-based behavioral change programs and applications. Founded in 2012, 2Morrow's offerings include SmartQuit, a smoking cessation program grounded in Acceptance and Commitment Therapy, My Pocket Coach, a platform for personal goal setting and habit formation, and Healthy Habits, designed to help individuals develop positive habits or eliminate detrimental ones. The company collaborates with employers, health plans, states, and wellness programs to make its programs accessible to those in need through digital platforms. By integrating technology with behavioral science, 2Morrow addresses significant health issues such as smoking, weight management, stress, and chronic pain, aiming to improve individual health outcomes.
HemaFlo Therapeutics, Inc. is an early stage company founded to commercialize a novel new device for the treatment of acute kidney injury and other ischemic conditions. The device is a very dilute solution of drag-reducing polymer (DRP) that is simply delivered intravenously to patients. Drag-reducing polymers have been studied in animals since the mid-1970’s and have shown dramatic benefits in disease models such as heart attack, hemorrhagic shock, diabetes, and atherosclerosis. The work has received little attention because the mechanism of action was unknown until just recently. HemaFlo Therapeutics has shown that drag-reducing polymers can be used to treat a very common and deadly condition that has a very attractive commercialization pathway. Acute kidney injury has no effective treatment and there are as many new cases in the US each year as for heart attacks, strokes, and cancer combined! Acute kidney injury is not widely perceived to be a serious problem because most cases occur in the hospital as a consequence of other diseases or procedures, resolve in a week or two, and the deaths are coded as heart failure (loss of regulation of electrolytes), respiratory failure (loss of regulation of fluids), or sepsis.
M&S Biotics, LLC is a healthcare technology company based in Scranton, Pennsylvania, established in 2014. It focuses on enhancing the efficiency, efficacy, and safety of surgical procedures through its innovative Biotic Integration system. This system utilizes radio frequency identification (RFID) technology and artificial intelligence to automate the counting of surgical items in real-time, thereby eliminating lengthy inventory protocols. Additionally, the company provides Biotic Insight, an analytics platform that offers valuable data regarding instrument utilization. By streamlining surgical processes, M&S Biotics aims to alleviate the financial pressures faced by hospitals and surgical facilities, enabling them to perform more surgeries annually and ultimately drive revenue growth.
Harbor MedTech, Inc. is a regenerative medicine company focused on developing and commercializing tissue regeneration products. Founded in 2010 and based in Irvine, California, the company offers a range of innovative solutions including Architect, an extracellular collagen matrix designed for managing various types of wounds such as diabetic ulcers, pressure sores, and surgical wounds. Additionally, Harbor MedTech provides NeuvoCell, a wound therapy specifically for chronic wounds, alongside products aimed at hernia and joint repair, orthopedic soft tissue repair, breast reconstruction, and urogynecological repair. Utilizing its BriDGE platform, the company is expanding its product pipeline to address needs in dermatology, general surgery, and plastic surgery. Harbor MedTech also maintains a strategic partnership with Edwards Lifesciences to enhance its offerings in the market.
Centerline Biomedical, Inc. is a Cleveland-based company founded in 2014, focused on developing advanced navigation systems for interventional vascular procedures. The company specializes in a non-x-ray based, three-dimensional GPS surgical navigation technology that enhances the precision and outcomes of endovascular procedures while significantly reducing radiation exposure for both patients and healthcare providers. This innovative system assists surgeons in accurately navigating catheters and guide wires through the complex three-dimensional anatomy of patients with vascular diseases, ultimately enabling safer and more effective image-guided surgeries. The technology is rooted in research and development from the Cleveland Clinic, highlighting its commitment to improving surgical practices in the medical field.
Evoke Medical is redefining the way orthopedic and spinal medical devices are researched, designed, and developed. They view things differently...They don't see the implant as a foreign object with the sole purpose of stabilizing or restoring motion. Instead, they view the implant as an integral part of the natural biochemical and biomechanical responses of the body postoperatively. They seek to mimic the bodies natural osteoinductive healing mechanisms via their implant designs.
PeriCor provides minimally invasive alternatives to infants, children and adults who require interventions including pacemakers, defibrillators or cardiac ablation procedures.
Access Vascular, Inc. is a medical technology company based in Bedford, Massachusetts, founded in 2015. The company specializes in developing venous access devices utilizing innovative hydrogel materials to significantly reduce the accumulation of blood components that can lead to thrombosis, infections, and other complications associated with intravenous therapy. Their product line includes peripherally inserted central catheters (PICC), hemodialysis access devices, implantable ports, and drug delivery systems. By addressing common issues in venous access, Access Vascular aims to improve clinical outcomes, decrease healthcare costs, and enhance patient experiences by minimizing morbidity, shortening hospital stays, and reducing pain. The company's initial focus is on launching the HydroPICC, which promises superior performance compared to existing technologies.
Nexeon MedSystems is a bioelectronics company developing active medical devices for the treatment of chronic medical conditions. The solutions we're developing are a unique blend of traditional device technologies such as electronics, software, mechanical engineering, and material science, as well as pharmaceuticals, protein chemistry, and cell biology.
Vadovations, Inc. is an Oklahoma City-based company that specializes in the design and manufacture of advanced healthcare equipment, particularly focusing on cardiac assist technologies. Founded in 2009, the company is developing a miniature ventricular assist device (VAD) that is smaller and lighter than existing models. This innovative blood pump allows for less invasive surgical implantation, significantly reducing hospitalization time from three weeks to just four days. The device is engineered for percutaneous delivery and endovascular deployment, minimizing risks associated with traditional blood pumps, such as stroke, bleeding, thrombosis, and infection. By addressing the limitations of current cardiac support systems, Vadovations aims to enhance treatment options for patients with end-stage heart failure while assisting cardiothoracic surgeons and interventional cardiologists in their procedures.
Palmm is a venture capital investment firm that specializes in developing innovative medical devices. One of its key products addresses the issue of excessive sweating, providing a convenient at-home treatment that targets specific body parts, such as the hands. The device employs a mild electrical current delivered through wearable garments to deactivate sweat glands, offering relief for several weeks. This solution aims to help individuals overcome the embarrassment associated with profuse sweating, allowing them to regain confidence in their everyday lives.
NXTSENS Microsystems is a performance leading fabless semiconductor company that provides tailored sensing, timing and frequency reference solutions. From prototype to full-scale production, NXTSENS provides an efficient path to commercial application.
OncoTAb, Inc., a North Carolina based startup, was co-founded by Mayo Clinic alumna Dr. Pinku Mukherjee, with a mission to improve the quality of cancer care by addressing unmet cancer diagnostic and therapeutic needs. The company’s first product, Agkura™ Personal Score, is a simple, non-invasive blood test offered as a supplement to mammography for women with dense breast tissue. Mammograms fail to detect cancer in 50% of women with high breast tissue density*, resulting in late stage diagnosis and mortality. The Agkura™ Personal Score shows a continuous trend of increasing values from benign disease through Breast Cancer Stages 1 to 4, with statistically significant increases prior to late stage breast cancer. Women with dense breast tissue can bi-annually monitor their personalized score in conjunction with annual mammograms. An increasing trend would indicate the need for additional imaging modalities and result in earlier stage diagnosis of breast cancer.
Nebula Industries
Grant in 2017
Nebula Industries is solving the problem of medical adhesive related injuries for those with fragile skin, particularly older people, using innovative approaches developed at MIT/Brigham and Women's Hospital.
Arterys Inc. is a technology company specializing in medical imaging analytics, aiming to enhance patient care through innovative solutions. Founded in 2007 and headquartered in San Francisco, California, with additional offices in Calgary and Paris, Arterys offers a cloud-based, AI-powered platform that enables radiologists to visualize and quantify blood flow in the body. Its product lineup includes Cardio AI for cardiac imaging, Lung AI for lung analysis, Liver AI for liver diagnostics, and Chest/MSK AI for detecting various thoracic and musculoskeletal conditions. The platform is fully web-based and FDA-cleared, providing clinicians with tools for automatic and interactive reporting. Additionally, the Arterys PHI Service allows physicians to access patient data remotely, further supporting efficient medical practices.
VerteCore is a developer of an innovative orthopedic medical device aimed at relieving lower back pain. The company has created the VerteCore Lift, a patent-pending system that offers a non-surgical approach to spinal decompression. This device targets various sources of back pain, including compressed or bulging discs, sciatica, and functional scoliosis, using a dual support harness and a unique ratcheting mechanism for ease of use. By providing a convenient and mobile solution, VerteCore enables active individuals to find rapid relief from spinal discomfort without the need for hospitalization, medication, or surgical intervention.
Patientory, Inc. is a healthcare technology company based in Atlanta, Georgia, that focuses on personal healthcare solutions. Founded in 2015, Patientory provides a platform that allows patients to manage their medical records and chronic illnesses while enabling healthcare providers to connect with patients effectively. The company's solution utilizes a blockchain-enabled network to gather and analyze healthcare data, offering insights that empower individuals to take charge of their health. By facilitating secure access to and management of health information, Patientory enhances care coordination among doctors, care providers, and patients, ultimately aiming to improve health outcomes and reduce healthcare costs.
Aqueduct Critical Care addresses the critical care problem of managing inter-cranial pressure. Its working prototypes demonstrate the ability to allow the patient to move, and minimize attention from nursing staff. Aqueduct Critical Care was founded in 2013 and is based in Bothell, Washington.
Voyager Biomedical, Inc. is committed to improving the lives of dialysis patients through the development of a novel vascular access device known as the ARK. The ARK has been designed to facilitate targeted needle placement and strengthen the vein by serving as a supportive exoskeleton. In addition, the ARK will increase patient comfort, and reduce stress and increase efficiency for caregivers, while benefiting the payer system by decreasing the surgeries necessary to enable long-term vascular access.
ITGI Medical is a bio-medical engineering company specializing in research and development, design, manufacture and distribution of high quality heterologous tissue covered stents for Cardiovascular and Neurovascular interventions. Their focus is on current technologies and applications that improve the standard of care for patients around the world in the fields of interventional Cardiology and Interventional Neuro-Radiology for the application in Coronary and neurological aneurysms, treatment of Fistulas, Saphenous Vein Graft occlusion (SVG Disease) and vascular perforations. Studies conducted prove that ITGI’s propriety technology can address these clinical problems in a safe and effective manner.
mOm Incubators Ltd. specializes in the development of electronically controlled inflatable infant incubators designed to reduce infant mortality rates, particularly among premature infants. Founded in 2014 and based in London, the company has created a collapsible incubator that provides thermoregulation comparable to traditional models. This innovative solution is versatile, catering to various environments, from rural areas in Africa to urgent neonatal transport in developed countries. mOm's incubators aim to create a safe and supportive environment for pre-term infants, addressing critical challenges faced in settings such as refugee camps, where conventional incubators may be impractical.
OpiSafe is a provider of platforms that manage the opioid response for various stakeholders, including prescribers, dispensers, public health agencies, first responders, and the general public. The company offers an opioid intelligence system designed to optimize prescriptions and improve healthcare outcomes. Its technology facilitates communication between patients and their care providers through a mobile application, allowing for more effective recovery and enhanced patient care. OpiSafe aims to bridge the gap between the opioid epidemic and the necessary solutions to address it.
Encellin, Inc. is a biotechnology company based in San Francisco, California, founded in 2015. It specializes in developing innovative cell-based therapeutics, particularly focusing on a novel thin-film cell encapsulation device. This device utilizes advanced thin-film cell delivery technology, which encapsulates and replaces cells, allowing the enclosed cells to operate as smart molecular factories. Encellin's primary mission is to provide effective treatments for patients with chronic diseases, with an initial emphasis on Type 1 diabetes. The company is committed to advancing next-generation therapies through the expertise of its dedicated team.
Abreos Biosciences develops lateral flow assays that measure the activity of high-value biologics. Its simple devices can be used for quality assurance, pharmacokinetic monitoring, and authentication in field, forensic, or point of care settings. We deliver value by enhancing brand protection, improving patients’ outcomes, and enabling rapid authentication for counterfeit prevention and end-user confidence.
The company was founded in 2013 and headquartered in San Diego, California.
Avenda Health Inc. is focused on developing a minimally invasive treatment for prostate cancer through its artificial intelligence-based focal laser ablation system. This innovative technology includes a fiber-optic laser and a disposable sensor, which work together with a feedback control system to provide precise treatments. The system integrates prostate images and biopsies using MRI-ultrasound fusion for guidance, allowing procedures to be performed under local anesthesia. Avenda Health aims to deliver safe, effective, and cost-efficient alternatives for patients, enhancing their quality of life while undergoing outpatient treatment. Founded in 2017, the company is headquartered in Santa Monica, California.
Nanowear, Inc. specializes in developing textile-based nanosensor technology designed for wireless and real-time electrophysiological monitoring. The company offers products like SimplECG, a remote cardiac monitoring undergarment, and SimpleSense, which focuses on monitoring and managing congestive heart failure. These garments capture multi-channel electrocardiogram (ECG), heart rate, and respiratory rate data, which is transmitted to a web-based portal for physician review via a mobile application. Nanowear's technology is versatile, finding applications in cardiac, neurological, industrial safety, government, sports medicine, and performance diagnostics. Founded in 2014, the company is headquartered in Brooklyn, New York, with a research and development facility located in University Park, Pennsylvania.
Day Zero Diagnostics (DZD) is developing a new class of diagnostic that enables a physician to switch from broad spectrum antibiotic therapy to a targeted antibiotic in 5 hours rather than the 2-5 days that it typically takes today. Unlike other molecular diagnostics that can only detect a handful of specific targets, DZD uses the entire genomic sequence and our proprietary Keynome™ algorithm to identify a comprehensive range of bacterial pathogens and their resistance characteristics within hours.
EBS Technologies GmbH, founded in 2007 and headquartered in Hennigsdorf, Germany, specializes in developing and commercializing medical devices aimed at treating neurologically induced impairments, particularly visual field loss. The company offers EBS Therapy, a non-invasive optic nerve stimulation treatment that utilizes low-voltage electrical currents to promote neuroregeneration and neuroprotection. This therapy targets conditions resulting from stroke, traumatic brain injury, and glaucoma, among others. With over 15 years of research and clinical experience involving more than 1,200 patients, EBS Technologies has demonstrated through double-blind, randomized studies and clinical observations that its therapy can help partially restore vision in affected individuals. The company received the CE Mark for its stimulation device in 2013 and commenced commercial treatments in 2014. Currently, there are eight EBS Treatment centers operating across Germany, with plans to expand the network further.
Genetesis LLC is a medical technology company focused on enhancing the diagnosis and management of cardiac conditions, specifically myocardial ischemia and coronary artery disease. Founded in 2013 and based in Mason, Ohio, Genetesis develops non-invasive biomagnetic imaging solutions, notably the Genetesis CardioFlux system. This advanced mapping technology allows for the detection and characterization of cardiac rhythm disorders by visualizing the heart's electrical currents in 3D. The company also utilizes the Faraday Analytical Cloud, a HIPAA-compliant platform that supports data management and workflow for the CardioFlux Magnetocardiograph (MCG). This innovative approach combines biomagnetic imaging with machine learning capabilities, aiming to improve patient health outcomes without exposing patients to radiation or requiring exercise during the procedure.
Alleviant Medical, Inc. is a medical device company focused on developing therapies for congestive heart failure. Founded in 2017 and headquartered in Austin, Texas, the company offers a proprietary transcatheter device designed to provide minimally invasive treatment for heart failure. This innovative technology aims to relieve pressure buildup in the left atrium, which can lead to organ failures, thereby alleviating symptoms of heart failure. By improving patients' quality of life and reducing hospital admissions due to heart failure exacerbations, Alleviant Medical addresses the needs of over 6 million Americans suffering from this condition.
Selio is a simple, effective and patent protected technology. The Selio prototype has been rigorously tested in the lab and in subsequent acute pre-clinical in vivo studies with very positive results.
PneuMotion provides continuous respiratory rate monitoring and obstructive apnea detection. PneuMotion seamlessly integrates into a hospital's existing network and allows mobile respiratory monitoring and EHR data collection. Ultra-low cost sensor technology makes this a cost-effective solution for opioid safety.
Synotrac is a novel, patent pending sensor technology that detects infection in vivo and alerts the patient and their physician in real time. The device quickly analyzes the body's immune response to give a dynamic picture of the joint's healing process, which enables detection of infection significantly earlier than other methods.
Advanced Prenatal Therapeutics (APT) is developing a novel therapeutic device for treating preeclampsia by specifically removing harmful substances from the mother’s blood.
AVA Health Technologies is building a disruptive software platform that addresses challenges in pediatric care for children with acute, chronic, and rare conditions Our vision is to fill the gap in funding and focus in dedicated pediatric research and to provide a collaborative ecosystem for care that can facilitate discovery of new cures.
Also modify BD: Enspectra Health, Inc. develops a system to image live cellular anatomy. Its system images beneath the skin and displays images in real-time. Enspectra Health, Inc. was formerly known as Zebra Medical Technologies. The company was incorporated in 2012 and is based in Mountain View, California.
Revolutionary Medical Devices, Inc. began June 2014 where it received critical acclaim at the Post-Graduate Assembly (PGA) for Anesthesiology. RMD has received worldwide recognition from Key Opinion Leaders in Anesthesia and its technologies are living up to their name, “Revolutionary”. The company’s mission is to utilize current clinical literature to drive the development of innovative technologies to optimize patient positioning during airway management and anesthesia. RMD develops airway management products to significantly improve anesthesiologist workload, O.R. turnover time, and easier patient intubation.
GreenLight Medical, Inc. is a cloud-based platform that facilitates the procurement process for medical devices within hospitals. Founded in 2014 and headquartered in Nashville, Tennessee, the company offers a software-as-a-service tool designed to enhance the decision-making process regarding medical technology purchases. The platform serves as a collaborative space for hospitals, medical suppliers, and other stakeholders, enabling streamlined workflows and effective project management. By connecting all parties involved, GreenLight Medical promotes cost-effective and quality-conscious purchasing decisions. It manages the entire sales cycle, from the introduction of medical device companies to their approval and use in healthcare facilities, providing actionable data and insights to improve the procurement process.
Adhesys Medical specializes in the development and manufacture of innovative polyurethane-based surgical adhesives designed for diverse applications both on the skin and internally. Their products utilize a unique polyurethane technology that distinguishes them from existing options in terms of ease of use, flexibility, biodegradability, and performance in wet environments. These advanced surgical sealants aim to enhance surgical procedures, improve patient comfort, and ultimately save lives by providing effective and reliable solutions for healthcare professionals.
Green Sun Medical, LLC is a medical device company established in 2013 and located in Fort Collins, Colorado. The company specializes in the design, development, and manufacturing of orthotic braces aimed at treating Adolescent Idiopathic Scoliosis (AIS) and Kyphosis. Its innovative products are designed to correct spinal deformities, providing support and alignment for patients with these conditions.
Adient’s mission is the development of absorbable medical devices with the premise that implants should be safe and efficacious during their useful lifetime, and then simply vanish without intervention, alleviating costly removal procedures and downstream complications.
C-SATS provides a personalized surgical skills assessment platform using a unique combination of data analytics, artificial intelligence. It specializes in the fields of robotic surgery, surgical skills, surgical insights, laparoscopic surgery, and minimally invasive surgery. The company was founded in 2014 and headquartered in Seattle, Washington.
IntuiTap Medical, Inc. is a Houston-based company that develops innovative devices for spinal punctures, addressing issues of inaccuracy and discomfort associated with these procedures. Founded in 2016, the company has created a handheld device that integrates imaging and needle guidance technology, providing a comprehensive solution for accurate needle placements used in lumbar punctures, spinal anesthesia, and epidurals. By enhancing the precision and efficiency of these procedures, IntuiTap Medical aims to reduce procedural costs and increase confidence among both healthcare providers and patients. The company's focus on improving spinal puncture outcomes positions it as a leader in this specialized medical field.
Adient’s mission is the development of absorbable medical devices with the premise that implants should be safe and efficacious during their useful lifetime, and then simply vanish without intervention, alleviating costly removal procedures and downstream complications.
PreDxion Bio is a precision medicine diagnostics company that provides ICU doctors with actionable patient immune function data. The company offers MicroKine, a diagnostic tool that measures patients’ immune responses. It enables doctors to identify up to six cytokine proteins using small blood volumes. Using this technology, physicians are able to tailor ICU treatments to each patient's needs. Founded in 2016, PreDxion Bio is based in Ann Arbor, Michigan.
WestFace Medical is a medical device company that has developed and patented needle tip imaging using OCT to improve vascular access. WestFace Medical presents a solution to the above needs - SingleStick™ - an imaging adapter utilizing optical coherence tomography (OCT) for pediatric vascular access. SingleStick™ consists of two components: a handheld imaging adapter (disposable component) and an OCT image processor (capital equipment component). The handheld imaging adapter leur locks to any hollow bore needle and subsequently introduces an optical fiber into the needle. The captured image from the needle tip is transmitted to an image processor providing a view of the needle’s trajectory. This view is real-time and forward facing. Traditional vascular access technique is hereby facilitated by real-time forward imaging. Accordingly, SingleStick™ provides multiple advantages over existing imaging technology.
Augmedics is a provider of augmented reality (AR) surgical image guidance solutions. Augmedics seeks to improve healthcare by developing cutting-edge technologies that will revolutionize surgical treatment. The company’s first product, the xvision-spine (XVS) system, is an augmented-reality surgical navigation system designed to allow surgeons to see and navigate inside a patient’s body during complex procedures.
Catalia Health Inc. is a San Francisco-based company that develops a cloud-based patient care management platform aimed at enhancing healthcare delivery. Established in 2014, the company integrates artificial intelligence, psychology, and medicine to improve patient engagement and support. Its platform provides healthcare providers with real-time data on patient progress and challenges, facilitating effective communication through mobile apps, web interfaces, and an interactive robotic coach. By delivering tailored conversations to patients, Catalia Health aims to address ongoing healthcare issues, ultimately enabling healthcare professionals to monitor adherence to treatment and improve overall patient outcomes.
Cor is a consumer product, with the intention of making it easy to access vital and valuable nutrition and fitness information through your blood. Cor transforms data through machine learning algorithms into “insights.” These insights are information for you based on your lifestyle changes. They include diet, supplements, exercise, and relaxation insights and recommendations. When something you try works for you, you will see an improvement in your indicators. That’s self-efficacy, and that’s just the beginning. You can take these insights and make them into habits. That’s adherence. Over time this becomes permanent improvement. Furthermore, you can share your successes with your family, or anyone you choose. You can help your community by sharing your secrets to success. Cor enables you to see inside your body, quickly and from the comfort of your own home. By providing personalized health insights and key indicator tracking, Cor empowers you to live a longer and healthier life.
SilverCloud Health Limited is a provider of online therapeutic solutions aimed at improving mental wellness. The company develops a platform that offers tailored clinical programs addressing various mental health issues, including emotional health. Founded in 2011 and headquartered in Boston, Massachusetts, with additional offices in Dublin, Ireland, and London, United Kingdom, SilverCloud Health delivers evidence-based digital therapies that enhance user engagement and reduce dropout rates compared to traditional online therapeutic products. By serving the healthcare, medical, and pharmaceutical sectors, SilverCloud Health enables individuals to access professional support quickly and affordably, promoting overall mental health and well-being.
SafeHeal is a medtech company focused on developing innovative medical devices specifically for digestive surgery. Established by MD Start, a medtech accelerator that brings physician inventions to market, SafeHeal has received funding from both MD Start and Sofinnova Partners. The company has been recognized for its contributions to the field, receiving accolades such as the Worldwide Innovation Challenge laureate in 2015 and the Charles Foix grant for its innovations aimed at enhancing the quality of life for elderly individuals. SafeHeal was also acknowledged as the most promising MedTech start-up at the Biovision 2016 investor conference and was a finalist in the global Medtech Innovator competition in 2016.
Linear Health Sciences is a medical device company creating products for various types of medical tubing based on its proprietary, breakaway safety-valve technology. This platform technology is designed to improve the healthcare experience for patients, caregivers, and healthcare facilities. The company has made substantial progress toward global patent protections and FDA clearance for the Orchid Safety Release Valve. There is a total addressable market of more than $1 billion annually for devices made by the company, which was founded by a physician and two engineers.
Tueo Health specializes in asthma management through the development of an innovative monitoring system aimed at improving control for children with asthma. The company offers a solution that combines accurate, objective indicators of asthma control with valuable clinical insights tailored to the needs of patients and their families. Utilizing a contactless sensor, the application enables users to monitor and manage asthma treatment progress effectively. This approach not only enhances understanding of asthma conditions but also supports families in achieving optimal health outcomes.
Madorra Their goal is empowering women to live fuller, healthier lives. Madorra is working towards changing the paradigm for treating vaginal dryness, by providing a medical device solution to a problem that has previously only been served by pharmaceuticals. They are focused on giving post-menopausal women and breast cancer survivors the power to choose the non-hormonal treatment option they want.
Spry Health, Inc. is a digital health solutions company based in Palo Alto, California, established in 2013. It specializes in developing a clinical-grade wearable device and a disease management platform designed to support chronically ill patients. The company's chargeable wristband monitors daily health and fitness activities, providing real-time analytics through a mobile application. This technology enables healthcare organizations to enhance patient outcomes, manage chronic conditions, prevent medical emergencies, and reduce hospitalizations and overall healthcare costs. Spry Health focuses on delivering individualized analytics that assist healthcare payers in efficiently managing the small percentage of patients who contribute significantly to health spending.
V-Sense Medical specializes in the development of remote medical monitoring devices that utilize advanced radar technology to monitor vital signs without direct contact with patients. By eliminating the need for traditional instruments such as wires, electrodes, and blood pressure cuffs, V-Sense Medical addresses significant challenges in medical facilities, including patient safety and comfort, measurement accuracy, and the efficiency of healthcare delivery. Their innovative approach allows for continuous monitoring of critical health metrics like heart rate and respiratory rate, providing healthcare professionals with real-time insights and alerts regarding patient health. This technology not only enhances the precision of medical assessments but also streamlines workflows, ultimately facilitating quicker and more effective patient care in urgent medical environments.
VETEX Medical is an Irish medical device company developing a revolutionary thrombectomy catheter to speedily extract thrombus in a single session, from patients who present with Venous Thrombo-Embolism. Vetex Medical has developed the Vetex thrombectomy catheter as a platform technology for the venous vascular system targeting deep vein thrombosis, AV Fistula grafts and pulmonary embolism. Initially Vetex Medical will target patients with acute DVT in the ilio-femoral veins. The venous thrombectomy market has been underserved for many years but is currently one of the key drivers of the clot management market as clinical evidence and awareness increases.
Sontina Medical is a healthcare technology company focused on developing innovative solutions for the breast biopsy market. Collaborating with leading physicians, Sontina Medical creates advanced technologies that allow for the safe and efficient collection of high-quality biopsy samples. Their products are designed to be accessible and affordable, offering unique features without the need for costly tools or capital equipment. By prioritizing both quality and affordability, Sontina Medical aims to enhance the biopsy procedures available to physicians and improve patient outcomes on a global scale.
Adient’s mission is the development of absorbable medical devices with the premise that implants should be safe and efficacious during their useful lifetime, and then simply vanish without intervention, alleviating costly removal procedures and downstream complications.
Disease Diagnostic Group (DDG) is a pre-revenue medical device company specializing in the development of rapid, accurate, and inexpensive disease diagnostic tests.
Mindera Health is a biotechnology company specializing in non-invasive molecular testing devices for skin cancer and other skin diseases. Founded in 2013 and based in Palo Alto, California, the company has developed innovative solutions such as a micro-needle array patch that allows for pain-free and targeted extraction of biomarkers, including RNA, DNA, and proteins, without the need for traditional skin biopsies. Mindera Health focuses on scalable technologies that facilitate the collection and evaluation of genetic data, enabling patients, healthcare professionals, and payers to make informed, data-driven decisions regarding treatment options. The company's advancements in biomarker identification and patient prediction analysis leverage deep learning to optimize treatment plans, particularly for conditions like psoriasis, where the technology helps identify patients best suited for specific biologic therapies.
Bloomlife is a women's health company focused on improving maternal health by addressing significant global challenges. It offers a comprehensive remote maternal care platform that combines connected devices with data analytics to enhance access to care and provide personalized feedback to expectant mothers. Central to Bloomlife's solution is a prenatal wearable device that monitors critical health parameters for both maternal and fetal well-being. This technology helps identify modifiable risk factors, detect abnormalities, and predict potential complications, enabling healthcare providers to manage pregnancies more effectively. By promoting early detection and intervention, Bloomlife aims to support families in achieving a healthy start.
MobileODT Ltd specializes in developing optical diagnostic devices and software focused on early cancer detection, particularly cervical cancer. The company's flagship product, the EVA COLPO, is a portable, internet-connected colposcope that is FDA-cleared and designed for ease of use. MobileODT also offers EVA SANE, a secure platform for managing patient information, and EVA WELL, a digital visualization tool for gynecologic exams. Their offerings include a mobile application for remote image capture and patient tracking, along with a cloud-based portal for collaboration and reporting. In addition, the company provides tools for documenting violence and abuse and plans to expand its product line to cover other medical areas such as ENT and dermatology. Established in 2012 and headquartered in Tel Aviv, Israel, with an office in New York, MobileODT has gained recognition in various markets, particularly the United States, where it is becoming a standard for visual diagnostics in healthcare settings.
Emmetrope is developing next-generation accommodative lenses. The holy grail of accommodative lenses must deliver a lens that accommodates at least two diopters, has a stable effect, is placed in the capsular bag and is compatible with modern cataract technique. Emmetrope is well on its way to achieving this goal. They are a small angel-funded company, but they have taken their first lens, called Actalens™, through clinical testing. The results, presented at ESCRS and currently in press, show that their lens outperforms other lenses in terms of anterior movement with accommodation. This accommodative movement has recently been independently validated and shown to be stable out to 20 months post surgery. Emmetrope, despite its size, now has best in class movement and stability of effect. Their final push toward the ultimate accommodative lens is about to begin. Computer modeling with finite element analysis demonstrates that their ActaLens platform, in its two layer embodiment, will yield a shape-change lens that offers over three diopters of accommodation. They are seeking series A financing to model, produce and clinically test this next generation shape change lens as well as take their first generation lens through CE mark and launch. The two year goal is specific and would have tremendous financial return for their company. They want to employ their validated Actalens platform to produce a shape-change lens with unprecedented objective accommodation.
PixelEXX Systems Inc. develops prototype imaging devices for diagnosing cancer. The products include nanoarrays that take images of molecular signals associated with cellular activity. PixelEXX Systems Inc. was founded in 2008 and is based in Saint Louis, Missouri.
Aperture Biomedical is a team of physicians and engineers working to improve vascular access for hemodialysis. As part of the Stanford Biodesign fellowship in medtech innovation, they identified a huge unmet clinical need: the two million people on dialysis depend on a sustainable method to access their blood supply. The life expectancy of an incidence dialysis patient is over five years but the current methods of access last less than a year, leading to expensive repairs and complications related to access management. To solve this need, their team designed a novel therapy to extend the patency of access and reduce downstream complications.
Developer of a health information exchange platform designed to create, store, and share advance care planning details. The company's platform offers advanced care technology related to health systems, acute care, and post-acute care facilities along with enhanced care management as well as provides patient education, and documentation, helping patients to make end-of-life care choices, manage their ongoing symptoms, and navigate the complex healthcare system.
Swift Health Systems Inc. is a medical device company based in Irvine, California, that specializes in developing innovative orthodontic solutions. The company's flagship product, INBRACE, is an invisible orthodontic system designed to correct malocclusion by being discreetly positioned behind the teeth. INBRACE employs patented self-guiding technology that utilizes light and continuous forces to gently adjust teeth, minimizing discomfort and reducing the frequency of doctor visits. FDA registered, INBRACE aims to make orthodontic treatment more appealing by addressing common patient concerns and facilitating practice growth for clinicians. The system integrates digital treatment planning, computer modeling, and direct digital manufacturing to offer a scalable and personalized approach to a wide range of orthodontic cases, thereby raising the standard of care in the field.
Vixiar Medical, Inc., founded in 2013 and located in Annapolis, Maryland, specializes in developing non-invasive and cost-effective medical devices for monitoring cardiopulmonary diseases. The company's flagship product, Indicor, is a handheld point-of-care device that enables healthcare professionals to monitor worsening heart failure. Vixiar's devices are designed to assess cardiac filling pressure in various settings, including homes, physician's offices, nursing homes, and hospitals. By focusing on improving clinical workflow and delivering economic value, Vixiar aims to address the significant clinical and economic burdens associated with cardiopulmonary conditions.
Cognition Medical Corp. is a medical device company based in Cambridge, Massachusetts, focused on developing innovative therapy solutions for acute stroke patients. Incorporated in 2012, the company specializes in devices that remove blood clots from the brain through minimally invasive techniques, eliminating the need for surgery. Their technology allows for navigation through catheters within blood vessels to safely retrieve clots while also protecting the brain from potential over-oxygenation that can occur after blocked vessels are reopened. Cognition Medical aims to improve the safety and efficiency of stroke procedures, ultimately reducing brain damage and promoting healthier outcomes for patients. The company combines expertise across various fields, including engineering, biology, and interventional medicine, to advance its mission.
uBiome, Inc. is a microbial genomics company based in San Francisco, California, founded in 2012. The company specializes in developing sequencing-based clinical microbiome tests, which include SmartGut, a test that identifies pathogenic and commensal microorganisms linked to infections, and SmartJane, a women's health screening test that assesses multiple conditions such as HPV and STIs. Additionally, uBiome offers Explorer kits for citizen scientists and researchers, as well as SmartFlu, a clinical respiratory test. The firm aimed to empower patients and healthcare providers by providing insights into the human microbiome and its impact on health. However, uBiome faced financial difficulties, filing for Chapter 11 bankruptcy in September 2019, which was subsequently converted to Chapter 7 on October 11, 2019.
Fosmo Med is innovating in the field of intravenous (IV) solutions by utilizing Forward Osmosis (FO) technology, which enables the production of IV bags using any available water source at the point of care. This approach allows the bags to be shipped without water, significantly lowering shipping costs, extending product shelf life, and minimizing storage expenses while reducing the risk of leakage. The technology is particularly aimed at organizations involved in disaster relief, such as the Red Cross and Doctors Without Borders, as it facilitates the conversion of non-potable water into a sterile 0.9 percent saline solution without the need for electrical power. This advancement not only enhances the safety and sterility of IV fluids but also helps combat dehydration-related diseases, making it a valuable solution in emergency situations. Fosmo Med has a patent pending on this innovative technology.
CytoChip Inc., founded in 2014 and based in Irvine, California, specializes in designing and manufacturing in vitro diagnostic devices. The company's flagship products include the CHIPNOW SYSTEM and CHIPNOW CARTRIDGES, which facilitate various diagnostic tests such as complete blood counts, lipid panels, and assessments of liver and kidney functions. These tests are tailored for use in physician offices and pharmacy clinics, addressing the need for accessible medical testing outside of centralized laboratories. CytoChip's innovative microfluidic technology allows users to perform tests using only a drop of blood obtained via fingerstick, with results delivered in about two minutes. This approach not only enhances patient care but also supports the financial viability of decentralized testing, with a market potential of approximately $1.2 billion annually for such services. By offering simple-to-use technology, CytoChip meets the growing demand for routine diagnostic tests in a more accessible and efficient manner.
MedAware Ltd specializes in developing solutions aimed at detecting and eliminating prescription errors to enhance patient safety and reduce healthcare costs. Founded in 2012 and headquartered in Raanana, Israel, the company utilizes advanced data analytics and machine learning algorithms to analyze extensive electronic medical records. Its offerings include the MedAS alerting system for real-time alerts on prescription errors, MedRIM for risk management support, MedQC for quality control assistance, and MedRAF to reduce alert fatigue. These tools enable healthcare providers, pharmacy benefit management companies, and pharmacy chains to leverage big data effectively, identify potential prescription errors related to drug interactions, dosages, and allergies, and ultimately improve patient outcomes.
Adult Medical Predictive Devices, Diagnostics and Displays, Inc. (AMP3D) has developed a platform for analytics and displays that makes sense of “Big Data” in health care. AMP3D at a glance enables earlier intervention and better outcomes by predicting potentially catastrophic events like emergent intubation, hemorrhage, and severe sepsis that can quadruple mortality and increase lengths-of-stay by more 9 days on average. AMP3D will use demonstrable return-on-investment to sell its platform as a service on a value-based pricing basis, aimed directly at quality measures and performance standards that impact reimbursement and payment. A 20% reduction in emergent intubations at a single medical ICU, for example, can save $600,000 annually; the addressable overall market opportunity for the in-patient market alone is in the billions of dollars.
Admetsys has developed a first-of-its-kind artificial pancreas for hospital and surgical care, leveraging adaptive learning algorithms and counterbalancing treatment of insulin and glucose.
The system has undergone 3 successful FDA-approved clinical trials with 97% control
between 80–125 mg/dl and zero incidents of low blood sugar.
Lightpoint Medical, Ltd., a medical device company, develops imaging technologies for cancer surgery. It develops Cerenkov Luminescence Imaging technology that detects cancer in real-time during surgery, and reduces the likelihood of cancer recurrence and the need for reoperation. Lightpoint Medical, Ltd. was formerly known as Artemis Diagnostics Ltd. and changed its name to Lightpoint Medical, Ltd. in January 2013. The company was founded in 2012 and is based in Rickmansworth, United Kingdom.
Diagnostic Photonics, Inc. specializes in advanced imaging technologies designed to aid physicians in the real-time assessment of tissue microstructure. Founded in 2008 and headquartered in Chicago, Illinois, the company has developed the Foresee Imaging System, which produces diffraction-corrected images to enhance tissue evaluation. The innovative imaging technology stems from research conducted at the Beckman Institute for Advanced Science and Technology at the University of Illinois, known for its interdisciplinary approach to scientific advancement.
TinyKicks is a technology company. It develops a wireless smart sensor system that captures fetal movement with machine learning to predict and guide healthy pregnancy outcomes. The company provides TinyKicks eMotion fetal activity monitor, a wearable band aid that senses the users baby kicks, and separates the baby’s kicks from its user’s own movements. The kicks are monitored continuously and the information is uploaded automatically to the user’s smartphone. TinyKicks was founded by France Helfer in 2014 and is headquartered in Irvine, California.
Nurep, Inc. is a company based in Palo Alto, California, founded in 2012, that provides support to medical device companies through its innovative mobile platform. This platform offers features such as product feeds, call pulse, live video, and analytics, facilitating effective communication and collaboration during surgical procedures. Nurep's technology enables remote surgeons and medical device representatives to securely access operating rooms via mobile devices, thereby enhancing the quality of operative care and improving surgical outcomes. The company's mission is to ensure that each patient receives optimal care during medical procedures.
Torix Medical has created the Innoflow device, a disruptive solution to treat urinary obstruction related to benign prostatic hyperplasia (BPH). This condition affects most men at some point in life and imposes a significant quality of life burden. Their device will provide durable symptom relief in a simple, office-based procedure using common flexible cystoscopy tools. This means that implantation is easier for the urologist and far less painful for the patient than with any other BPH device. They have a strong IP position, a 510(k) FDA pathway, established reimbursement precedents, and an extremely quick and capital-efficient path to market. They have achieved excellent cadaver results to demonstrate that the mechanism works. They’re now beginning animal studies and will get to first-in-man in late 2015.
Surgisense specializes in the design, development, testing, manufacturing, and marketing of innovative new technologies for medical devices. We focus on developing the next generation of “smart” sensing surgical instruments and medical devices to further enhance surgery, patient care, and patient safety.
Bionic Vision Technologies Pty Ltd is an Australian company focused on developing visual prostheses aimed at restoring vision to individuals affected by blindness, particularly those with inherited retinal diseases. Founded in 2007 and based in Carlton, the company creates a suprachoroidal visual implant system that works by electrically stimulating the remaining retinal cells in patients with retinal degeneration. The innovative devices operate by capturing images through a camera mounted on an eyeglass frame, which are then converted into electrical signals. These signals stimulate the nerves using electrodes placed behind the retina, allowing visual information to be transmitted to the brain. Through this technology, Bionic Vision Technologies seeks to improve the quality of life for blind patients by enhancing their eyesight.
UnaliWear Inc., based in Austin, Texas, develops the Kanega watch, a multipurpose wearable designed for seniors to maintain independence and dignity. This discreet device offers features such as fall detection, medication reminders, and assistance for individuals who may wander, all through a voice-activated interface. The Kanega watch is equipped with various technologies, including cellular, Wi-Fi, GPS, and Bluetooth, allowing it to provide emergency support anywhere without the need for a smartphone. Its patented battery system ensures that the watch remains charged without requiring removal. Additionally, the device incorporates data-driven artificial intelligence to learn the user’s lifestyle, enabling it to offer predictive and preemptive assistance tailored to individual needs.
2C Tech Corporation, based in Irvine, California, is a biotech company specializing in the development of medical devices that utilize nanotechnology for ophthalmic applications. The company's flagship product, SeeQ, employs intraocularly delivered photoactive nanoparticles to convert light into electrical energy, functioning similarly to a solar cell. 2C Tech is dedicated to creating innovative therapies for retinal degenerative conditions, particularly focusing on Retinitis Pigmentosa, a disease for which there are currently no effective treatments. The company's research also aims to address other serious eye conditions, including certain forms of Macular Degeneration, Glaucoma, and Diabetic Retinopathy, which affect larger patient populations. By leveraging its expertise in nanoparticle technologies, 2C Tech seeks to provide meaningful therapeutic benefits for those suffering from these debilitating diseases.
IntelliDrain, Inc. is a medical device company commercializing a novel chest drainage technology. Backed by human clinical trials and based on original research, IntelliDrain technology provides clinicians with decision support for timely removal of chest tubes, as well as therapeutically guiding and promoting lung healing. Application of our technology enables patients to go home sooner, avoids complications, and saves healthcare costs.
Francis Lamont Innovations (FLI) is an innovative spin-out from an established design / engineering business with a focus on novel electro-mechanical devices to assist surgeons in more effective/less invasive surgical procedures, Our primary product is a novel medical device, the ‘Francis Lamont Orthopaedic Table Extension’ – ‘FLOTE’ – designed to assist surgeons in direct anterior (DAA) hip replacement surgery. FLOTE is a patented device that facilitates and simplifies a difficult ‘minimally invasive’ surgical procedure so that it may be more widely adopted. It is a low-cost, portable device that is designed to greatly exceed the performance of any existing devices at a fraction of the cost. We have proven surgical evidence of the device’s efficacy, as well as patient benefits and outcomes.
Fibralign Corporation utilizes Nanoweave® a proprietary scaffolding technology to develop advanced biomedical devices. Fibralign has launched its first product, the BioBridge® Collagen Matrix, and is now engaging in clinical studies to evaluate its use for treating and preventing secondary lymphedema, as well as advancing R&D development for new applications for treating ischemia and novel delivery devices for use with stem cells and gene therapy.
CystoSure is a medical device company focused on enhancing the cystoscopy process for female patients and their healthcare providers. The company has developed an innovative device that simplifies intraoperative cystoscopy, addressing the limitations of traditional methods that can be complicated and cumbersome. CystoSure's design integrates a 3-way urinary catheter with a specially designed telescope, allowing for safe and efficient visualization of the female bladder. This advancement enables doctors to conduct diagnostic cystoscopy without the need to remove the drainage catheter, promoting a more standardized and user-friendly approach in the evaluation of lower urinary tract conditions.
ChemoFilter is developing a novel catheter device enables chemotherapy delivery in a targeted manner, reducing patient side effects and improving treatment efficacy. The ChemoFilter device filters chemotherapeutics from the bloodstream, preventing toxic drugs from leaving the tumor site. ChemoFilter’s first version will treat unresectable liver cancer, the 3rd leading cause of cancer death with over 600,000 new cases per year by working in tandem with trans-arterial chemoembolization (TACE), the current standard of care for this disease. ChemoFilter will save the healthcare system over $5,000 per patient, while increasing hospital and physician margins and improving patient care. ChemoFilter has potential worldwide sales of over $1 billion in liver cancer with the opportunity to expand into other cancers. A UCSF based startup, ChemoFilter is supported by seed grants from UCSF, Society of Interventional Radiology, and the prestigious NIH Small Business Technology Transfer (STTR) grant.